Headlines about Athersys (NASDAQ:ATHX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Athersys earned a news impact score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3327670859821 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern’s scoring:
- Athersys (ATHX) Announces Earnings Results, Misses Estimates By $0.04 EPS (americanbankingnews.com)
- Stock’s Technical Levels Evaluation – Athersys Inc (NASDAQ: ATHX) – Stocks Pen (stockspen.com)
- Hot Stock That Must Be in Your Portfolio: Athersys Inc (NASDAQ: ATHX) – Alpha Beta Stock (alphabetastock.com)
- A Bombshell Day For Athersys: Earnings, Partnership, And New Indications – Seeking Alpha (seekingalpha.com)
- Athersys, Inc.: Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem Collaboration (finanznachrichten.de)
Athersys (NASDAQ:ATHX) traded up $0.11 during midday trading on Wednesday, hitting $1.95. 1,048,939 shares of the stock traded hands, compared to its average volume of 638,102. Athersys has a 12-month low of $1.10 and a 12-month high of $2.63. The company has a market cap of $243.45, a price-to-earnings ratio of -7.50 and a beta of -0.57.
ATHX has been the subject of several recent analyst reports. Maxim Group reiterated a “buy” rating and issued a $6.00 target price on shares of Athersys in a research note on Tuesday. ValuEngine upgraded shares of Athersys from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd.
In related news, COO William Lehmann, Jr. sold 14,000 shares of the stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $1.80, for a total transaction of $25,200.00. Following the completion of the transaction, the chief operating officer now owns 503,712 shares in the company, valued at $906,681.60. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $51,075. 9.40% of the stock is owned by company insiders.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.